Jubilant Life Sciences' subsidiary to initiate clinical trial to treat neuroblastoma

Jubilant Life Sciences has announced that its subsidiary Jubilant Pharma Limited has initiated Optimum trial, which is a pivotal Phase II clinical trial, designed to prove the safety and effectiveness of I-131 MIBG for the treatment of neuroblastoma. This will be taking place through Jubilant Pharma's unit Jubilant DraxImage Inc. in Montreal, Canada.

The study will be conducted on both male and female patients over the age of one year who show a return of this disease following initial therapy. Children will receive up to two dose cycles of I-131 MIBG over a twenty-six week period. The trial results will be submitted to USFDA under the Orphan Drug Designation programme and is eligible for accelerated approval if the clinical trials are successful.

On Friday, the stock of Jubilant Life Sciences hit its intra-day high at Rs 747.35 and intra-day low of Rs 722.50 and closed at Rs.741.35, down by 0.90 per cent on the BSE.